Chronic kidney disease: Cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition

Experimental Physiology

Volumn 97, Issue 4, 2012, Pages 477-485

  Burrell, L M ^a   Burchill, L ^a   Dean, R G ^a   Griggs, K ^a   Patel, S K ^a   Velkoska, E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; MESSENGER RNA; RAMIPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY FUNCTION; NEPHRECTOMY; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; RAT; SUBTOTAL NEPHRECTOMY;

EID: 84859635766     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2011.063156     Document Type: Article

References (43)

1. Allred AJ, Chappell MC, Ferrario CM & Diz DI (2000). Differential actions of renal ischemic injury on the intrarenal angiotensin system. Am J Physiol Renal Physiol 279, F636-F645.
2. Burchill L, Velkoska E, Dean RG, Lew RA, Smith AI, Levidiotis V & Burrell LM (2008). Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. Exp Physiol 93, 622-630.
3. Burrell LM, Johnston CI, Tikellis C & Cooper ME (2004). ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 15, 166-169.
4. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME & Johnston CI (2005). Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26, 369-375; discussion 322-364.
5. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME & Gilbert RE (2001). Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 60, 715-721.
6. Chappell MC, Pirro NT, Sykes A & Ferrario CM (1998). Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension 31, 362-367.
7. Couser WG & Riella MC (2011). Cardiovascular disease: World Kidney Day 2011: protect your kidneys, save your heart. Nat Rev Nephrol 7, 130-132.
8. Dean RG, Balding LC, Candido R, Burns WC, Cao Z, Twigg SM & Burrell LM (2005). Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem 53, 1245-1256.
9. Díez-Freire C, Vázquez J, Correa de Adjounian MF, Ferrari MF, Yuan L, Silver X, Torres R & Raizada MK (2006). ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics 27, 12-19.
10. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE & Acton S (2000). A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87, E1-E9.
11. Ferrario CM (2011). ACE2: more of Ang-(1-7) or less Ang II? Curr Opin Nephrol Hypertens 20, 1-6.
12. Ferrario CM, Ahmad S, Joyner J & Varagic J (2010). Advances in the renin angiotensin system: focus on angiotensin-converting enzyme 2 and angiotensin-(1-7). Adv Pharmacol 59, 197-233.
13. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI & Gallagher PE (2005a). Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111, 2605-2610.
14. Ferrario CM, Trask AJ & Jessup JA (2005b). Advances in the biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in the regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289, H2281-H2290.
15. Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RA, Katovich MJ & Raizada MK (2011). Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 96, 287-294.
16. Gembardt F, Sterner-Kock A, Imboden H, Spalteholz M, Reibitz F, Schultheiss HP, Siems WE & Walther T (2005). Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 26, 1270-1277.
17. Go AS, Chertow GM, Fan D, McCulloch CE & Hsu CY (2004). Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351, 1296-1305.
18. Grobe JL, Der Sarkissian S, Stewart JM, Meszaros JG, Raizada MK & Katovich MJ (2007). ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci (Lond) 113, 357-364.
19. Guy JL, Lambert DW, Warner FJ, Hooper NM & Turner AJ (2005). Membrane-associated zinc peptidase families: comparing ACE and ACE2. Biochim Biophys Acta 1751, 2-8.
20. Hamming I, van Goor H, Turner AJ, Rushworth CA, Michaud AA, Corvol P & Navis G (2008). Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats. Exp Physiol 93, 631-638.
21. Herath CB, Warner FJ, Lubel JS, Dean RG, Jia Z, Lew RA, Smith AI, Burrell LM & Angus PW (2007). Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol 47, 387-395.
22. Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA & Raizada MK (2008). Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 51, 1312-1317.
23. Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC & Ferrario CM (2006). Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol 291, H2166-H2172.
24. Levey AS, de Jong PE, Coresh J, Nahas ME, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL & Eckardt KU (2010). The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 80, 17-28.
25. Mackie FE, Campbell DJ & Meyer TW (2001). Intrarenal angiotensin and bradykinin peptide levels in the remnant kidney model of renal insufficiency. Kidney Int 59, 1458-1465.
26. Meyer TW & Rennke HG (1988). Progressive glomerular injury after limited renal infarction in the rat. Am J Physiol Renal Physiol 254, F856-F862.
27. Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, Khokha R, Crackower MA, Backx PH, Penninger JM & Scholey JW (2006). Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 168, 1808-1820.
28. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM, Herzenberg AM, Kassiri Z & Scholey JW (2010). Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59, 529-538.
29. Rosenberg ME, Correa-Rotter R, Inagami T, Kren SM & Hostetter TH (1991). Glomerular renin synthesis and storage in the remnant kidney in the rat. Kidney Int 40, 677-683.
30. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R & Walther T (2003). Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100, 8258-8263.
31. Soler MJ, Wysocki J, Ye M, Lloveras J, Kanwar Y & Batlle D (2007). ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 72, 614-623.
32. Taal MW & Brenner BM (2008). Adaptation to nephron loss. In The Kidney, vol. 8, ed. Brenner BM & Rector FC, pp. 783-819. Saunders, Philadelphia
33. Tikellis C, Bialkowski K, Pete J, Sheehy K, Su Q, Johnston C, Cooper ME & Thomas MC (2008). ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 57, 1018-1025.
34. Tikellis C, Cooper ME, Bialkowski K, Johnston CI, Burns WC, Lew RA, Smith AI & Thomas MC (2006). Developmental expression of ACE2 in the SHR kidney: a role in hypertension? Kidney Int 70, 34-41.
35. Trask AJ, Groban L, Westwood BM, Varagic J, Ganten D, Gallagher PE, Chappell MC & Ferrario CM (2010). Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. Am J Hypertens 23, 687-693.
36. Velez JC (2009). The importance of the intrarenal renin-angiotensin system. Nat Clin Pract Nephrol 5, 89-100.
37. Velkoska E, Dean RG, Burchill LJ, Levidiotis V & Burrell LM (2010). Reduction in renal ACE2 expression in subtotal nephrectomy is ameliorated with ACE inhibition. Clin Sci (Lond) 118, 269-279.
38. Velkoska E, Dean RG, Griggs K, Burchill LJ & Burrell LM (2011). Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clin Sci (Lond) 120, 335-345.
39. Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, Liu QC, Backx PH, Penninger JM, Herzenberg AM & Scholey JW (2007). Loss of angiotensin-converting enzyme-2 (ACE2) accelerates diabetic kidney injury. Am J Pathol 171, 438-451.
40. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S & Batlle D (2006). ACE and ACE2 activity in diabetic mice. Diabetes 55, 2132-2139.
41. Yamada K, Iyer SN, Chappell MC, Ganten D & Ferrario CM (1998). Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension 32, 496-502.
42. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS & Batlle D (2004). Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 43, 1120-1125.
43. Ye M, Wysocki J, William J, Soler MJ, Cokic I & Batlle D (2006). Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 17, 3067-3075.